President of Dangote Group, Aliko Dangote, has called on Nigeria and other African countries to pursue medical sovereignty through sustained investment in regenerative medicine, local research, manufacturing and healthcare innovation.
Dangote made the call while delivering the keynote address at the Atunse Summit in Lagos, where government officials, industry leaders and regulators examined the role of regenerative medicine and public-private partnerships in strengthening Nigeria’s healthcare system.
He said Africa must move from being a major consumer of advanced medical technologies to becoming a producer of cutting-edge healthcare solutions.
According to him, African countries need to build the capacity to prevent, detect, treat and respond to health challenges with greater self-reliance.
Dangote described medical sovereignty as both a healthcare objective and a strategic development priority, arguing that countries capable of protecting the health of their populations are better positioned to grow their economies, retain skilled professionals, attract investment and respond to public health emergencies.
He cited India, Brazil, China and Indonesia as examples of countries that have strengthened their healthcare industries through sustained investment in science, technology transfer and consistent policies.
The businessman, however, stressed that healthcare innovation must lead to affordable and accessible treatment for ordinary citizens rather than remain concentrated in elite hospitals and major urban centres.
Zebra News reports that the summit also focused on reducing Nigeria’s dependence on imported medical technologies and developing local capacity across research, treatment, manufacturing and healthcare services.
Speaking at the event, President and Chairman of Atunse Healthcare Ltd., Professor Kamar Adeleke, said the company was established to address the long-standing practice of Nigerians and other Africans travelling abroad for advanced medical treatment.
Adeleke said although the initiative began in Lagos, its long-term objective was to develop healthcare capacity across Africa.
The Chief Executive Officer of Atunse Healthcare Ltd., Dr Sola Oluwole, said Nigeria loses more than financial resources through medical tourism.
He said the country also loses potential investment, clinical demand and opportunities to develop specialist expertise when patients travel abroad for treatment.
Oluwole said Atunse plans to develop integrated capabilities covering treatment, manufacturing, distribution and workforce development within Nigeria.
Representing Lagos State Governor Babajide Sanwo-Olu, the Commissioner for Health, Professor Akin Abayomi, described regenerative medicine as one of the most promising areas of modern healthcare.
Abayomi said investments in the sector could encourage Nigerian doctors, scientists and other healthcare professionals working abroad to return and contribute to the country’s healthcare development.
He also said the Lagos State Government was strengthening digital healthcare through its Smart Health Information Platform (SHIP).
According to him, integrating health data, technology, medical specialists and private-sector investment would improve healthcare planning, encourage innovation and strengthen the delivery of advanced medical services.
Zebra News reports that the National Agency for Food and Drug Administration and Control (NAFDAC) also stressed the need for strict regulation of regenerative medicine.
Representing the agency’s Director-General, the Director of the Vaccine, Biologics and Medical Devices Registration and Regulation Directorate, Mrs Khadijah Ade-Abolade, said regenerative medicine offered significant opportunities but required rigorous oversight.
She explained that biologics and cell-based therapies differ significantly from conventional medicines and therefore require specialised regulatory processes.
Ade-Abolade said NAFDAC remained committed to supporting healthcare innovation while ensuring that regenerative medicine products met required standards for safety, quality and efficacy.
She said the agency would subject such products to comprehensive scientific reviews, ethical clinical trials, strict manufacturing oversight and post-market surveillance.
NAFDAC also pledged to support credible researchers and local manufacturers while taking enforcement action against operators promoting unapproved regenerative therapies.
The agency maintained that healthcare innovation must not compromise patient safety.

